Eli Lilly is among the top 15 competitors in the $191 billion worldwide ethical pharmaceutical market and must decide on the type of manufacturing strategy for their new pharmaceuticals to remain competitive. Their objectives include increasing new product speed to market by 50% and reducing the cost of manufacturing by 25%. The issues facing the company’s manufacturing strategy decision are numerous. The pharmaceutical industry’s average annual growth rate in 1982 through 1992 was 18%; however
Premium Pharmacology Supply and demand Drug
Competing through Strategy Case: Eli Lilly in India: Rethinking the Joint Ventures Strategy I. Brief Summary Global pharmaceuticals had presence in India since early 80’s and it was not until 1993 that Eli Lilly International decided to establish a Joint Venture with India’s second largest laboratory and exporter‚ Ranbaxy. This move happened in a very challenging context as both companies have very different profiles and backgrounds. The main differential characteristic was the nature
Premium Strategic management Joint venture Generic drug
Eli Lilly in India: Rethinking the Joint Venture Strategy Case Analysis Question No. 1 First‚ at the time Eli Lilly and Ranbaxy joint forces‚ Indian regulations limited foreign ownership to a maximum 51 percent. Therefore‚ a joint venture with a local leading company was an excellent option for Eli Lilly to begin penetrating the Indian Market. Secondly‚ India was a sensitive market with a lot of incoming competition‚ lack of intellectual property and low per capita gross domestic product. For that
Premium Trademark Brand Eli Lilly and Company
Case Context Set in 1993‚ the case focuses on a difficult decision faced by Steve Mueller‚ manager of strategic facilities and planning at Eli Lilly‚ about the type of manufacturing facility to construct for the three new pharmaceutical products that the company plans to launch in 1996. A number of growing industry and company specific conditions have made this decision particularly relevant and have sparked debate with management and throughout the company. In response to these conditions‚ Lilly
Premium Net present value
Eli Lilly: Developing Cymbalta Case Study 1: Analysis The given discussion is based on Eli Lilly‚ a research-based pharmaceutical company. The first core strategy of Eli Lilly and company was to replace its premier drug “Prozac” before losing its patent. The second is differentiating the company and its brand. Lilly began concentrating and devoting its resources to other possible assets: R-fluoxetine‚ OFC (olanzapine-fluoxetine combination)‚ 5HT2 Antagonist‚ SSRI‚ Business Development Opportunities
Premium Pharmacology Clinical trial Marketing
but the population of India cannot be ignored. And 200 million and 300 million of 800 million people in India were middle class. That was a huge potential market for Eli Lilly and Company. As the cost of health-care increased in developed countries in the 1990s‚ chose India was a good choice for a international company like Eli and Lilly. Especially could uses India as trade route to export products to Russia‚ so choose India had a lot of advantages. 2. Was deciding to partner wrong? Is partnership
Premium Corporation Joint venture India
traditional approach used for organizing development projects at Eli Lilly? This consists of two issues. First‚ is an evaluation of the changes taking place in the pharmaceutical industry and what it is that caused Lilly to feel compelled to try the heavyweight development approach on two of its drug development projects? Second‚ is understanding the essence of the heavyweight team approach‚ particularly as it has been used by Lilly? A Heavyweight team structure is a project management organizational
Premium Project management
Eli Lilly and Company:Drug Development Strategy Assignment One RSM494: Technological Strategy 2/16/2012 Antora Sanchari Ahmed 997292139 Professor Terry Amburgey TABLE OF CONTENTS Executive Summary………………………………………………………………………..3 Market Analysis……………………………………………………………………………4 Industry Analysis………………………………………………………………………….5
Premium Pharmaceutical industry Drug discovery Clinical trial
heavyweight team at Lilly. • First‚ the teams were each given a very clear business charter “to focus exclusively on the development of a single compound.” • Second‚ each team was collocated and cross functional. • Third‚ the teams were each led by a “heavyweight” project manager. • Fourth‚ each team took responsibility for the sub-stance of the work‚ how the work was accomplished‚ and the ensuing results. • Fifth‚ each team had two executive sponsors‚ one from LRL (Lilly Research Laboratories)
Premium Clinical trial Drug development Project management
Case# 6 - Eli Lilly: The Elvista Project 1. What is a "heavyweight project team" and how does it differ from the traditional approach used for organizing projects at Eli Lilly? Their traditional approach was much less organized and personal. Heavy weight teams at Eli Lilly were setup so that specialized individuals would work on one project (as opposed to several) led by a project manager. The project manager would then designate individual jobs and make sure that they were completed. Five key
Premium Project management Eli Lilly and Company Team